Our panel sequencing identified 58 patients (7 CM, 40 AM, and 11 MM) with potentially actionable mutations amenable to approved or off‐label drug targeting, along with 31 patients (27 CM and 4 AM) with melanoma with clinically detectable BRAF V600E/K mutations. Here, BRAF is linked to melanoma.